| 1 |
Simon HU, Mills GB, Kozlowski M, et al. Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation[J]. Biochem J, 1994, 297(Pt 2): 389-397.
|
| 2 |
Park Y, Luger K. The structure of nucleosome assembly protein 1[J]. Pro Natl Acad Sci USA, 2006, 103(5): 1248-1253.
|
| 3 |
黄 艳，周 政. H2A-H2B类型组蛋白及其伴侣蛋白的研究进展[J]. 生物化学与生物物理进展，2018, 45(9): 971-980.
|
| 4 |
Okuwaki M, Kato K, Nagata K. Functional characterization of human nucleosome assembly protein 1-like proteins as histone chaperones[J]. Genes Cells, 2010, 15(1): 13-27.
|
| 5 |
Lee JY, Lake RJ, Kirk J, et al. NAP1L1 accelerates activation and decreases pausing to enhance nucleosome remodeling by CSB[J]. Nucleic Acids Res, 2017, 45(8): 4696-4707.
|
| 6 |
Tanaka T, Hozumi Y, Iino M, et al. NAP1L1 regulates NF-κB signaling pathway acting on anti-apoptotic Mcl-1 gene expression[J]. Biochim Biophy Acta Mol Cell Res, 2017, 1864(10): 1759-1768.
|
| 7 |
Tanaka T, Hozumi Y, Martelli AM, et al. Nucleosome assembly proteins NAP1L1 and NAP1L4 modulate p53 acetylation to regulate cell fate[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(12): 118560.
|
| 8 |
Yan Y, Yin P, Gong H, et al. Nucleosome assembly Protein 1-Like 1 (Nap1l1) regulates the proliferation of murine induced pluripotent stem cells[J]. Cell Physiolo Biochem, 2016, 38(1): 340-350.
|
| 9 |
Qiao H, Li Y, Feng C, et al. Nap1l1 controls embryonic neural progenitor cell proliferation and differentiation in the developing brain[J]. Cell Reports, 2018, 22(9): 2279-2293.
|
| 10 |
Sun S, Li X, Liu Z, et al. Expression of nucleosome assembly protein 1 like genes in zebrafish embryos[J]. Gene Expr Patterns, 2020, 35: 119076.
|
| 11 |
Sun S, Liu Z, Li X, et al. Characterization of a nap1l1 transgenic reporter in zebrafish[J]. Gene, 2020, 735: 144388.
|
| 12 |
Su L, Song X, Xue Z, et al. Network analysis of microRNAs, transcription factors, and target genes involved in axon regeneration[J]. J Zhejiang University-SCIENCE B, 2018, 19(4): 293-304.
|
| 13 |
Chen Z, Gao W, Pu L, et al. PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1[J]. Hepatology, 2018, 68(3): 994-1009.
|
| 14 |
Huang Y, Xiang B, Liu Y, et al. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis[J]. Cancer Lett, 2018, 437: 56-66.
|
| 15 |
Le Y, Kan A, Li Q, et al. NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma[J]. Cancer Cell Int, 2019, 19(1): 228.
|
| 16 |
Meshram CD, Agback P, Shiliaev N, et al. Multiple host factors interact with the hypervariable domain of chikungunya virus nsP3 and determine viral replication in cell-specific mode[J]. J Virol, 2018, 92(16): e00838-18.
|
| 17 |
Goonawardane N, Gebhardt A, Bartlett C, et al. Phosphorylation of serine 225 in hepatitis C virus NS5A regulates protein-protein interactions[J]. J Virol, 2017, 91(17): e00805-17.
|
| 18 |
Cevik RE, Cesarec M, Da SFA, et al. Hepatitis C virus NS5A targets nucleosome assembly protein NAP1L1 to control the innate cellular response[J]. J Virol, 2017, 91(18): e00880-17.
|
| 19 |
Yin P, Li Y, Zhou L, et al. NAP1L1 regulates hepatitis C virus entry and interacts with NS3[J]. Virol Sin, 2018, 33(2): 205-208.
|
| 20 |
Kidd M, Modlin IM, Mane SM, et al. The role of genetic markers-NAP1L1, MAGE-D2, and MTA1-in defining small-intestinal carcinoid neoplasia[J]. Ann Surg Oncol, 2006, 13(2): 253-262.
|
| 21 |
Queiroz CJS, Song F, Reed KR, et al. NAP1L1: A novel human colorectal cancer biomarker derived from animal models of Apc inactivation[J]. Front Oncol, 2020, 10: 1565.
|
| 22 |
Aydin MA, Gul G, Kiziltan R, et al. Nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility[J]. Eur Rev Med Pharmacol Sci, 2020, 24(20): 10512-10517.
|
| 23 |
Modlin IM, Kidd M, Latich I, et al. Genetic differentiation of appendiceal tumor malignancy[J]. Ann Surg, 2006, 244(1): 52-60.
|
| 24 |
Schimmack S, Taylor A, Lawrence B, et al. A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases[J]. Epigenetics Chromatin, 2014, 7(1): 15.
|
| 25 |
Jovcevska I, Zupanec N, Urlep Ž，et al. Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates[J]. Oncotarget, 2017, 8(27): 44141-44158.
|
| 26 |
Zottel A, Jovcevska I, Šamec N, et al. Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration[J]. Ther Adv Med Oncol, 2020, 12: 386353034.
|
| 27 |
Nagashio R, Kuchitsu Y, Igawa S, et al. Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma[J]. Biomed Res, 2020, 41(3): 149-159.
|
| 28 |
Al-Dhaheri MH, Shah YM, Basrur V, et al. Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells[J]. Steroids, 2006, 71(11-12): 966-978.
|
| 29 |
Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia[J]. Nature, 2012, 481(7380): 157-163.
|
| 30 |
Bond J, Touzart A, Cieslak A, et al. NAP1L1-MLLT10 is a rare recurrent translocation that is associated with HOXA activation and poor treatment response in T-cell acute lymphoblastic leukaemia[J]. Br J Haematol, 2016, 174(3): 470-473.
|
| 31 |
Guidi F, Puglia M, Gabbiani C, et al. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds[J]. Mol Biosyst, 2012, 8(4): 985-993.
|
| 32 |
Zhai W, Ma J, Zhu R, et al. MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis[J]. Br J Cancer, 2018, 119(5): 591-604.
|